Microsponges: A Novel Strategy for Drug Delivery System

Overview

Journal J Adv Pharm Technol Res

Date 2012 Jan 17

PMID 22247859

Citations 16

Authors

Santanu Kaity

Sabyasachi Maiti

Ashoke Kumar Ghosh

Dilipkumar Pal

Animesh Ghosh

Subham Banerjee

Affiliations

Soon will be listed here.

Abstract

Microsponges are polymeric delivery systems composed of porous microspheres. They are tiny sponge-like spherical particles with a large porous surface. Moreover, they may enhance stability, reduce side effects and modify drug release favorably. Microsponge technology has many favorable characteristics, which make it a versatile drug delivery vehicle. Microsponge Systems are based on microscopic, polymer-based microspheres that can suspend or entrap a wide variety of substances, and can then be incorporated into a formulated product such as a gel, cream, liquid or powder. The outer surface is typically porous, allowing a sustained flow of substances out of the sphere. Microsponges are porous, polymeric microspheres that are used mostly for topical use and have recently been used for oral administration. Microsponges are designed to deliver a pharmaceutical active ingredient efficiently at the minimum dose and also to enhance stability, reduce side effects, and modify drug release.

Citing Articles

A systematic review of nanocarriers used in medicine and beyond - definition and categorization framework.

Gressler S, Hipfinger C, Part F, Pavlicek A, Zafiu C, Giese B J Nanobiotechnology. 2025; 23(1):90.

PMID: 39920688 PMC: 11804063. DOI: 10.1186/s12951-025-03113-7.

Nanocosmeceuticals: Trends and Recent Advancements in Self Care.

Sethi M, Rana R, Sambhakar S, Chourasia M AAPS PharmSciTech. 2024; 25(3):51.

PMID: 38424412 DOI: 10.1208/s12249-024-02761-6.

Microsponge-Based Gel Loaded with Immunosuppressant as a Simple and Valuable Strategy for Psoriasis Therapy: Determination of Pro-Inflammatory Response through Cytokine IL-2 mRNA Expression.

Mehmood Y, Shahid H, Ul Huq U, Rafeeq H, Khalid H, Uddin M Gels. 2023; 9(11).

PMID: 37998961 PMC: 10670748. DOI: 10.3390/gels9110871.

Alginate Microsponges as a Scaffold for Delivery of a Therapeutic Peptide against Rheumatoid Arthritis.

Ariaudo D, Cavalieri F, Rinaldi A, Aguilera A, Lopez M, Perez H Nanomaterials (Basel). 2023; 13(19).

PMID: 37836350 PMC: 10574729. DOI: 10.3390/nano13192709.

Impact of Topical Vehicles and Cutaneous Delivery Technologies on Patient Adherence and Treatment Outcomes in Acne and Rosacea.

Gold L, Kwong P, Draelos Z, Arekapudi K, Levy-Hacham O, Erlich M J Clin Aesthet Dermatol. 2023; 16(5):26-34.

PMID: 37288283 PMC: 10243731.

References

Embil K, NACHT S . The Microsponge Delivery System (MDS): a topical delivery system with reduced irritancy incorporating multiple triggering mechanisms for the release of actives. J Microencapsul. 1996; 13(5):575-88. DOI: 10.3109/02652049609026042. View

Comoglu T, Gonul N, Baykara T . Preparation and in vitro evaluation of modified release ketoprofen microsponges. Farmaco. 2003; 58(2):101-6. DOI: 10.1016/s0014-827x(02)00007-1. View

Wakiyama N, Juni K, Nakano M . Preparation and evaluation in vitro of polylactic acid microspheres containing local anesthetics. Chem Pharm Bull (Tokyo). 1981; 29(11):3363-8. DOI: 10.1248/cpb.29.3363. View

Chen G, Sato T, Ohgushi H, Ushida T, Tateishi T, Tanaka J . Culturing of skin fibroblasts in a thin PLGA-collagen hybrid mesh. Biomaterials. 2004; 26(15):2559-66. DOI: 10.1016/j.biomaterials.2004.07.034. View

Wester R, Patel R, NACHT S, Leyden J, Melendres J, Maibach H . Controlled release of benzoyl peroxide from a porous microsphere polymeric system can reduce topical irritancy. J Am Acad Dermatol. 1991; 24(5 Pt 1):720-6. DOI: 10.1016/0190-9622(91)70109-f. View

Orlu M, Cevher E, Araman A . Design and evaluation of colon specific drug delivery system containing flurbiprofen microsponges. Int J Pharm. 2006; 318(1-2):103-17. DOI: 10.1016/j.ijpharm.2006.03.025. View

Iwai S, Sawa Y, Taketani S, Torikai K, Hirakawa K, Matsuda H . Novel tissue-engineered biodegradable material for reconstruction of vascular wall. Ann Thorac Surg. 2005; 80(5):1821-7. DOI: 10.1016/j.athoracsur.2005.03.139. View

Iwai S, Sawa Y, Ichikawa H, Taketani S, Uchimura E, Chen G . Biodegradable polymer with collagen microsponge serves as a new bioengineered cardiovascular prosthesis. J Thorac Cardiovasc Surg. 2004; 128(3):472-9. DOI: 10.1016/j.jtcvs.2004.04.013. View

Kawashima Y, Niwa T, Takeuchi H, Hino T, Ito Y . Control of prolonged drug release and compression properties of ibuprofen microspheres with acrylic polymer, eudragit RS, by changing their intraparticle porosity [corrected]. Chem Pharm Bull (Tokyo). 1992; 40(1):196-201. DOI: 10.1248/cpb.40.196. View

10.

Kanematsu A, Marui A, Yamamoto S, Ozeki M, Hirano Y, Yamamoto M . Type I collagen can function as a reservoir of basic fibroblast growth factor. J Control Release. 2004; 99(2):281-92. DOI: 10.1016/j.jconrel.2004.07.008. View

11.

Kawashima Y, Niwa T, Takeuchi H, Hino T, Itoh Y, Furuyama S . Characterization of polymorphs of tranilast anhydrate and tranilast monohydrate when crystallized by two solvent change spherical crystallization techniques. J Pharm Sci. 1991; 80(5):472-8. DOI: 10.1002/jps.2600800515. View

12.

Washburn E . Note on a Method of Determining the Distribution of Pore Sizes in a Porous Material. Proc Natl Acad Sci U S A. 1921; 7(4):115-6. PMC: 1084764. DOI: 10.1073/pnas.7.4.115. View

13.

Chen G, Ushida T, Tateishi T . A biodegradable hybrid sponge nested with collagen microsponges. J Biomed Mater Res. 2000; 51(2):273-9. DOI: 10.1002/(sici)1097-4636(200008)51:2<273::aid-jbm16>3.0.co;2-o. View

14.

Franz T . Percutaneous absorption on the relevance of in vitro data. J Invest Dermatol. 1975; 64(3):190-5. DOI: 10.1111/1523-1747.ep12533356. View

15.

Sato T, Kanke M, SCHROEDER H, Deluca P . Porous biodegradable microspheres for controlled drug delivery. I. Assessment of processing conditions and solvent removal techniques. Pharm Res. 1988; 5(1):21-30. DOI: 10.1023/a:1015855210319. View

16.

Grimes P . A microsponge formulation of hydroquinone 4% and retinol 0.15% in the treatment of melasma and postinflammatory hyperpigmentation. Cutis. 2005; 74(6):362-8. View